Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 3 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Population burden (prevalence, incidence, lifetime risk) All modifiable factors together | Prevention |
No direction reported
whyA pooled incidence and prevalence estimate with no exposure compared, so no direction is recorded. |
Pooled incidence and prevalence of frontotemporal dementia | meta-analysis | not stated | Pooled crude incidence for FTD was 2.28 (95% CI, 1.55-3.36) per 100 000 person-years and prevalence, 9.17 (95% CI, 3.59-23.42) per 100 000 people |
JAMA Neurology
2025 ✓ Peer-reviewed PMID 40920400 |
| Population burden (prevalence, incidence, lifetime risk) All modifiable factors together | Prevention |
No direction reported
whyA pooled prevalence estimate with no exposure compared, so there is no direction to record. |
Global prevalence of young-onset dementia (ages 30-64) | meta-analysis | 2,760,379 | Age-standardized prevalence estimates increased from 1.1 per 100 000 population in the group aged 30 to 34 years to 77.4 per 100 000 population in the group aged 60 to 64 years. This gives an overall global age-standardized prevalence of 119.0 per 100 000 population in the age range of 30 to 64 years, corresponding to 3.9 million people aged 30 to 64 years living with YOD in the world |
JAMA Neurology
2021 ✓ Peer-reviewed PMID 34279544 |
| Polygenic risk / GWAS loci Genes (not modifiable) | Prevention |
No direction reported
whyLocus-discovery genome-wide association study: it reports which genetic regions reached significance and no effect estimate for any exposure, so no direction is recorded. The study reports 14 new loci for clinically diagnosed AD and two from AD-by-proxy. |
Genome-wide significant loci for clinically diagnosed AD and AD-by-proxy | meta-analysis | 432,374 | not established — pubmed abstract lists the loci by name and reports no effect estimate. |
Alzheimer's & Dementia
2025 ✓ Peer-reviewed PMID 39998322 |